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AbstrACt
Objectives Insight in the prescribing quality for patients 
with chronic kidney disease (CKD) in secondary care is 
limited. The aim of this study is to assess the prescribing 
quality in secondary care patients with CKD stages 3–5 
and possible differences in quality between CKD stages.
Design This was a retrospective cohort study.
setting Data were collected at two university (n=569 and 
n=845) and one non-university nephrology outpatient 
clinic (n=1718) in the Netherlands.
Participants Between March 2015 and August 2016, data 
were collected from patients with stages 3a–5 CKD seen 
at the clinics. Blood pressure measurements, laboratory 
measurements and prescription data were extracted from 
medical records. For each prescribing quality indicator, 
patients with incomplete data required for calculation were 
excluded.
Outcome measures Potentially appropriate prescribing 
of antihypertensives, renin-angiotensin-aldosterone 
system (RAAS) inhibitors, statins, phosphate binders 
and potentially inappropriate prescribing according to 
prevailing guidelines was assessed using prescribing 
quality indicators. Χ2 or Fisher’s exact tests were used to 
test for differences in prescribing quality.
results RAAS inhibitors alone or in combination with 
diuretics (57% or 52%, respectively) and statins (42%) 
were prescribed less often than phosphate binders (72%) 
or antihypertensives (94%) when indicated. Active vitamin 
D was relatively often prescribed when potentially not 
indicated (19%). Patients with high CKD stages were less 
likely to receive RAAS inhibitors but more likely to receive 
statins when indicated than stage 3 CKD patients. They 
also received more active vitamin D and erythropoietin-
stimulating agents when potentially not indicated.
Conclusions Priority areas for improvement of prescribing 
in CKD outpatients include potential underprescribing of 
RAAS inhibitors and statins, and potential overprescribing 
of active vitamin D. CKD stage should be taken into 
account when assessing prescribing quality.
IntrODuCtIOn
Assessing quality of care in chronic kidney 
disease (CKD) patients is important for iden-
tifying areas for improvement. Several recent 
studies have shown that detection of CKD, 
monitoring of disease progression and meta-
bolic parameters and achievement of risk 
factor target levels are suboptimal in CKD 
care.1–4 Three of these studies showed that 
prescribing of selected medication treatment 
may also be suboptimal, for example, showing 
potential underprescribing of renin-angio-
tensin-aldosterone system (RAAS) inhibitors 
and statins, and overprescribing of non-ste-
roidal anti-inflammatory drugs (NSAIDs) 
in primary care patients with CKD. In addi-
tion, one study showed an increasing trend 
in prescribing of RAAS inhibitors and statins 
in secondary CKD patients.5 Not much is 
known about differences in prescribing 
quality in CKD patients between healthcare 
organisations.
Recently, our research group has developed 
a set of prescribing quality indicators (PQIs) 
for assessing the prescribing quality in patients 
with CKD according to clinical guideline 
recommendations, which has been validated in 
a primary care population.6 The set is intended 
also for secondary care, and includes several 
indicators that are specifically relevant for 
patients with higher CKD stages. The PQIs give 
strengths and limitations of this study
 ► Quality of prescribing was assessed with validated 
quality indicators measuring both potential appro-
priate and inappropriate prescribing taking individ-
ual patient characteristics into account.
 ► Quality of prescribing was compared between pa-
tients with different CKD stages and from different 
outpatient clinics.
 ► Quality of prescribing was assessed in a cross-sec-
tional manner, which disregards longitudinal aspects 
of care.
 ► There were differences in patient population and 
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new insights in quality of prescribing in CKD patients, since 
they assess a broad range of prescribing issues at patient 
level and incorporate patient characteristics that are rele-
vant for treatment decisions. Previously it was found that 
with increasing CKD stages prescribing of RAAS inhibitors 
and NSAIDs decreased, while prescribing of phosphate 
binders, vitamin D and erythropoietin-stimulating agents 
(ESA) increased.1 However, this was based on the number 
of prescriptions regardless of whether the medication was 
indicated for the included patients. The aim of this study is 
to assess prescribing quality in secondary care patients with 
CKD stages 3a–5 using PQIs that take relevant patient char-
acteristics into account. Differences in prescribing quality 
between patients with different CKD stages were evaluated. 
In a secondary analysis, also differences between different 
outpatient clinics in the Netherlands were explored.
MethODs
This was a retrospective cross-sectional study assessing the 
prescribing quality between March 2015 and August 2016 
in the Netherlands in two university nephrology outpatient 
clinics A and B, and one non-university nephrology outpatient 
clinic C. Included were patients with CKD stages 3a–5 based 
on estimated glomerular filtration rate (eGFR), that is stage 
3a was defined as an eGFR ≥45 and<60 mL/min/1.73 m2, 
stage 3b as an eGFR ≥30 and<45 mL/min/1.73 m2, stage 4 
as an eGFR ≥15 and<30 mL/min/1.73 m2 and stage 5 as an 
eGFR <15 mL/min/1.73 m2.7 Patients who received dialysis 
or renal transplantation were excluded from the study.
The medical ethical committee of the University 
Medical Center Groningen ascertained that this study 
using anonymised medical record data does not fall under 
the Medical Research Involving Human Subjects Act.
Clinics and setting
Clinic A and clinic B are academic hospitals, which 
provided data from their general nephrology outpatient 
clinic and their predialysis outpatient clinic. Clinic C is a 
nonacademic, public hospital, which provided data from 
the general nephrology outpatient clinic. Twelve months of 
consecutive data were collected from 1June 2015 to 31 May 
2016 for clinic A, from 1 March 2015 to 29 February 2016 
for clinic B and 1 September 2015 to 31 August 2016 for 
clinic C. In all three clinics, the included CKD patients 
commonly visit the outpatient clinics 2–4 times per year 
depending on the progression of their disease. At these 
visits, all medication can be reviewed and changed based 
on a medication list which is available for the nephrolo-
gist. In all clinics, the medication included in this study is 
usually prescribed by the nephrologist or nephrologist in 
training, although other specialists or the general practi-
tioner may also prescribe medication during the year. Visits 
for the nephrology and the predialysis outpatient clinics 
are conducted in a similar way. All patients collect their 
medication at community pharmacies, where medication 
reviews may be conducted regardless of the outpatient 
clinic they visit. All patients have similar access to prescribed 
medication.
Prescribing quality
A previously developed set of patient-oriented PQIs was 
used for the assessment of prescribing quality of patients 
with CKD not undergoing renal replacement therapy.6 
This set was based on clinical guideline recommenda-
tions. The PQIs intend to provide insight in prescribing 
behaviour of physicians with regard to antihypertensives, 
RAAS inhibitors, statins and phosphate binders when 
recommended (potentially appropriate prescribing) as 
well as prescribing of dual RAAS blockade, active vitamin 
D, ESA, NSAIDs, metformin and digoxin when consid-
ered not needed or unsafe (potentially inappropriate 
prescribing) (table 1). To specify the indicators to specific 
needs of patients, most indicators focus on a subgroup 
of the population selected based on kidney function, 
risk factor levels and/or age as described in the clinical 
guidelines or added by the expert panel in the develop-
ment phase. Since there will always be individual cases for 
whom this is not the case, we speak of ‘potentially’ appro-
priate (or inappropriate) prescribing. Antihypertensives 
include diuretics, beta blocking agents, calcium channel 
blockers, agents acting on the RAAS system and other 
antihypertensives such as centrally acting agents. Diuretics 
include all types of diuretics, for example low-ceiling 
and high-ceiling diuretics and potassium-sparing agents. 
RAAS inhibitors include angiotensin-converting-enzyme 
inhibitors and angiotensin-receptor blockers. In the 
Netherlands, this medication is reimbursed by the health 
insurance after the patient’s annual deductible excess has 
been exceeded. This is the same for all three clinics.
Data collection
For each patient with at least one visit to a nephrologist 
within the study period, blood pressure measurement, 
laboratory measurements and prescription data of the 
most recent visit were extracted from the medical records, 
either by manual (clinic A) or computerised (clinics B 
and C) extraction routines. Age was determined on the 
visit day. For some patients, the visit date was unknown, 
in which case the most recent date of the eGFR assess-
ment was used as a proxy for the visit date. The eGFR was 
calculated from serum creatinine using the modification 
of diet in renal disease (MDRD) formula.8 If serum creati-
nine was not available, the reported eGFR calculated with 
the MDRD formula was used. Proteinuria was defined as 
more than 0.5 g of protein in 24 hours or per litre urine, 
depending on availability.
Patient and public involvement
Patients or public were not directly involved in this study. 
Three patient representatives were, however, involved in the 
development phase of the PQIs applied in this study to ascer-
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statistical analysis
Means with SD are reported for normally distributed 
continuous variables, medians with interquartile ranges 
for non-normally distributed variables and percentages 
for categorical variables. The PQI scores are presented as 
percentages with 95% CI. Χ2 or Fisher’s exact tests, in case 
of cell frequencies below 5, were used to test for differ-
ences in prescribing quality across different CKD stages 
and different clinics. P-values<0.05 were considered 
statistically significant. When comparing individual PQIs 
between CKD stages or clinics, Bonferroni correction for 
multiple testing was applied. Analyses were conducted 
using Stata V.14.2 special edition (Stata Corporation).
results
In total, 3132 patients with CKD stage 3a-5 were included 
in this study. Included patients were on average 68 years 
(SD: 14) old, 56% were males, the median eGFR was 
35 mL/min/1.73 m2 (IQR: 24–46) and 16% had diabetes. 
Patients with higher CKD stages more often had blood 
pressure and laboratory measurements (table 2).
Overall prescribing quality
Two PQIs focusing on prescribing of RAAS inhibitors in 
patients with micro-albuminuria and diabetes were not 
operational valid in this population because of the limited 
availability of albumin/creatinine ratios (indicators 3 
Table 1 Indicator definitions for the PQIs
Nr. Indicator definition
Appropriate prescribing
1 The percentage of patients between 18 and 80 years with CKD stages 4–5 and hypertension* that is prescribed 
antihypertensives unless undesirable because of low diastolic blood pressure (<70 mm Hg)
2 The percentage of patients between 18 and 80 years with CKD stages 3–5 and proteinuria† that is prescribed an 
ACE-i or ARB
3 The percentage of patients between 18 and 80 years with CKD stages 3–5, micro-albuminuria‡ and diabetes§ that 
is prescribed an ACE-I or ARB
4 The percentage of patients between 18 and 80 years with CKD stages 3–5 and proteinuria† treated with multiple 
antihypertensives that is prescribed a combination of an ACE-i or ARB and a diuretic
5 The percentage of patients between 18 and 80 years with CKD stages 3–5, micro-albuminuria‡ and diabetes§ 
treated with multiple antihypertensives that is prescribed a combination of an ACE-I or ARB and a diuretic
6 The percentage of patients between 50 and 65 years with CKD stages 3–5 that is prescribed a statin
7 The percentage of patients between 18 and 80 years with CKD stages 3–5 and an elevated phosphate level 
(>1.49 mmol/L) that is prescribed a phosphate binder
8 The percentage of patients between 18 and 80 years with CKD stages 3–5 treated with phosphate binders and 
with an elevated calcium level (>2.54 mmol/L) that is prescribed a non-calcium-containing phosphate binder
9 The percentage of patients between 18 and 80 years with CKD stages 3–5 treated with phosphate binders and 
with a low calcium level (<2.10 mmol/L) that is prescribed a calcium-containing phosphate binder
Inappropriate prescribing
10 The percentage of patients 18 years or older with CKD stages 3–5 treated with RAAS inhibitors that is prescribed 
at least two RAAS inhibitors simultaneously (dual RAAS blockade)
11 The percentage of patients 18 years or older with CKD stages 3–5 and an elevated calcium level (>2.54 mmol/L) 
that is prescribed active vitamin D
12 The percentage of patients 18 years or older with CKD stages 3–5 and a normal haemoglobin level (≥7.5 mmol/L) 
that is prescribed an ESA
13 The percentage of patients 18 years or older with eGFR<30 mL/min/1.73 m2 that is prescribed an NSAID
14 The percentage of patients 18 years or older with eGFR<30 mL/min/1.73 m2 and diabetes§ that is prescribed 
metformin
15 The percentage of patients 18 years or older with eGFR<50 mL/min/1.73 m2 treated with digoxin that is prescribed 
high-dose digoxin (>0.125 mg/day)
16 The percentage of patients 18 years or older with CKD stages 3–5 that is prescribed a combination of NSAIDs, 
RAAS inhibitors and diuretics
*Hypertension is defined as having a systolic blood pressure >140 mm Hg or being prescribed antihypertensives.
†Proteinuria is defined as >0.5 g protein per 24 hours or l urine or albumin/creatinine ratio ≥30 mg/mmol.
‡Micro-albuminuria is defined as albumin/creatinine ratio ≥3.0 mg/mmol and <30 mg/mmol. 
§Diabetes is defined as either the diagnosis for diabetes or being prescribed with glucose lowering drugs. 
ACE-i, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; eGFR, estimated 
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and 5). Furthermore, two PQIs focusing on prescribing 
of non-calcium-containing and calcium-containing phos-
phate binders in patients with high and low calcium levels, 
respectively, were not operational valid because of the low 
inclusion of eligible patients (indicators 8 and 9). These 
four PQIs were excluded from further analysis.
Potentially appropriate prescribing rates varied from 
94% of patients receiving antihypertensives, 57% and 52% 
receiving RAAS inhibitors alone or in combination with a 
diuretic, 42% receiving statins and 72% receiving phos-
phate binders when indicated according to the guideline 
(figure 1). Potentially inappropriate prescribing rates 
varied from 19% of patients receiving active vitamin D, 
3% receiving ESA, 1% receiving NSAIDs, 3% receiving 
metformin and 4% receiving high-dose digoxin when this 
was possibly not needed or unsafe.
Prescribing quality across chronic kidney disease stages
Potential appropriate prescribing of RAAS inhibitors 
alone occurred significantly less in patients with CKD 
stage 5 compared with all other stages, which was also 
true for the combination of RAAS inhibitors and diuretics 
(figure 2). Patients with stage 3a were less likely to receive 
recommended treatment with statins than patients with 
stage 4 or 5. Similarly, patients with stage 3b were less likely 
to receive statins compared with patients with stage 4. 
Potential inappropriate prescribing of active vitamin D in 
patients with elevated calcium occurred significantly less 
in patients with stages 3a and 3b compared with patients 
with stages 4 and 5. This was also the case for potentially 
inappropriate prescribing of ESA. Finally, potentially 
inappropriate prescribing of metformin in patients with 
an eGFR <30 mL/min/1.73 m2 was significantly lower for 
stage 5 compared with stage 4.
Prescribing quality across nephrology outpatient clinics
Patients visiting the university outpatient clinics A and B 
were on average younger (63 years (SD: 15) and 65 years 
(SD: 15)) compared with those visiting the non-univer-
sity outpatient clinic C (71 years (SD: 13)). Furthermore, 
patients visiting clinic A more often had CKD stage 4 or 
5 compared with patients from clinics B and C (table 2). 
The diabetes prevalence was higher at clinic A (26%) 
compared with clinic B (19%) and clinic C (10%) (online 
supplementary table 1).
Significant differences were seen between clinic A 
and clinic C in potentially appropriate prescribing of 
antihypertensives, RAAS inhibitors alone, statins and 
in potentially inappropriate prescribing of metformin 
as well as the combination of NSAIDs, RAAS inhibitors 
Figure 1 Overall prescribing quality assessed with five prescribing quality indicators (PQIs) for appropriate prescribing 
(ind 1–7) and seven PQIs for potential inappropriate prescribing (ind 10–16). Ind 1: patients with hypertension prescribed 
antihypertensives; ind 2: patients with albuminuria prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors; ind 4: 
patients on multiple antihypertensives prescribed a combination of RAAS inhibitors and diuretics; ind 6: patients aged 50–65 
years prescribed statins; ind 7: patients with high phosphate levels prescribed phosphate binders; ind 10: patients prescribed 
dual RAAS blockade; ind 11: patients with high calcium levels prescribed active vitamin D; ind 12: patients with normal 
haemoglobin levels prescribed erythropoietin-stimulating agents; ind 13: patients with an estimated glomerular filtration rate 
(eGFR) lower than 30 mL/min/1.73 m2 prescribed high-dose non-steroidal anti-inflammatory drugs (NSAIDs); ind 14: patients 
with diabetes and an eGFR lower than 30 mL/min/1.73 m2 prescribed metformin; ind 15: patients with an eGFR lower than 
50 mL/min/1.73 m2 prescribed high-dose digoxin; ind 16: patients prescribed a combination of NSAIDs, RAAS inhibitors and 
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and diuretics (figure 3). Furthermore, significantly more 
potentially appropriate prescribing of phosphate binders 
was seen in clinic A compared with clinic B.
In the analyses per CKD stage (online supplementary 
tables 2 and 3), similar differences were found between 
the clinics. In patients with stage 3a CKD, potentially 
appropriate prescribing of RAAS inhibitors combined 
with diuretics occurred the least in clinic B. In patients 
with stage 3b CKD, potential appropriate prescribing 
of RAAS inhibitors alone or combined with diuretics 
occurred the most in clinic A. Patients with stage 4 CKD 
were significantly more likely in clinic A compared with 
clinic C to receive antihypertensives and RAAS inhibitors 
alone. Also, patients with CKD stage 5 were more likely 
in clinic A compared with clinic C to receive phosphate 
binders when indicated.
DIsCussIOn
This is the first study to assess the prescribing quality 
in secondary care CKD patients using a broad set of 
patient-oriented PQIs and comparing patients with 
different CKD stages and from different outpatient 
clinics. The results show that the prescribing quality 
seems to vary between therapeutic areas. RAAS inhibi-
tors and statins were prescribed in less than 60% of the 
patients for whom this is potentially indicated, whereas 
prescribing rates for antihypertensives and phosphate 
binders when potentially indicated were much higher. 
Active vitamin D was prescribed in almost one fifth of 
all patients while considered potentially not needed or 
unsafe. The prescribing levels also varied across different 
CKD stages, with decreasing prescribing of RAAS inhib-
itors, increasing prescribing of statins and increasing 
prescribing of active vitamin D and ESA with higher CKD 
stages. Finally, significant differences were observed in 
prescribing between the different outpatient clinics, also 
after stratification for CKD stage.
Previous studies looking at the overall volume of 
prescribing suggested that there was underprescribing 
of RAAS inhibitors and statins1 5 and overprescribing of 
NSAIDs1 in patients with CKD. In addition, it was shown 
that patients with higher CKD stages receive more treat-
ment with antihypertensives, phosphate binders, vitamin 
D and ESA than patients with lower CKD stages.1 9 On 
the other hand, RAAS inhibitors and NSAIDs were less 
prescribed with increasing CKD stages.1 These studies, 
Figure 2 Prescribing quality across different chronic kidney disease (CKD) stages (3a–5) assessed with five PQIs for 
appropriate prescribing (ind 1–7) and seven PQIs for potential inappropriate prescribing (ind 10–16). Ind 1: patients with 
hypertension prescribed antihypertensives; ind 2: patients with albuminuria prescribed renin-angiotensin-aldosterone system 
(RAAS) inhibitors; ind 4: patients on multiple antihypertensives prescribed a combination of RAAS inhibitors and diuretics; ind 
6: patients aged 50 to 65 years prescribed statins; ind 7: patients with high phosphate levels prescribed phosphate binders; 
ind 10: patients prescribed dual RAAS blockade; ind 11: patients with high calcium levels prescribed active vitamin D; ind 
12: patients with normal haemoglobin levels prescribed erythropoietin-stimulating agents; ind 13: patients with an estimated 
glomerular filtration rate (eGFR) lower than 30 mL/min/1.73 m2 prescribed high-dose non-steroidal anti-inflammatory drugs 
(NSAIDs); ind 14: patients with diabetes and an eGFR lower than 30 mL/min/1.73 m2 prescribed metformin; ind 15: patients with 
an eGFR lower than 50 mL/min/1.73 m2 prescribed high-dose digoxin; ind 16: patients prescribed a combination of NSAIDs, 
RAAS inhibitors and diuretics. 95% CIs were calculated based on included number of patients in the denominator of each 
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however, did not take the specific indications for treat-
ment into account. Our study using validated PQIs, which 
assess prescribing in patients for whom this is indicated, 
confirmed that potential underprescribing of RAAS inhib-
itors and statins may be areas for possible improvement in 
CKD care. This was also found in a recent study among 
patients with stages 3–4 CKD in Canada.3 In some patients 
with CKD stage 5 who are in preparation of dialysis or 
transplantation, RAAS inhibitors may be deliberately 
stopped to retain the residual kidney function.10 Lower 
statin prescribing rates in patients with lower CKD stages 
suggest that prescribers may be less aware or convinced of 
the need to prescribe statins in these patients. A similar 
pattern of less statin prescribing in patients with a higher 
eGFR compared with lower eGFR was observed for the 
elderly primary care patients in Canada.11 Regarding 
potentially inappropriate prescribing, the Canadian 
primary care study observed a relatively high prescribing 
rate of NSAIDs (16%) and low prescribing rate of dual 
RAAS blockade (3%). Our study showed that poten-
tially unsafe prescribing of both NSAIDs and dual RAAS 
blockade was uncommon in secondary care patients 
managed in the Netherlands.
Although the applied PQIs are patient-oriented, taking 
relevant patient characteristics into account, they reflect 
general guideline recommendations, and therefore a 
perfect score is never pursued. There can be valid reasons 
to refrain from prescribing according to guideline recom-
mendations in certain patients. Valid reasons include 
lack of response to certain drugs, drug intolerances or 
patient preferences for or against certain treatment. For 
example, hyperkalaemia could be a reason to stop treat-
ment with RAAS inhibitors. The assessment using PQIs 
is therefore useful to provide insight and monitor the 
quality of care at population level and not to assess the 
quality of treatment for each individual patient. Further-
more, it has been argued that patient case-mix including 
difference in aspects, such as age or comorbidities, may 
explain differences in quality scores.12 However, these 
may not necessarily be valid reasons for not complying 
with guideline recommendations. When developing the 
PQIs, such differences are to some extent included in the 
indicator definitions (eg, age limits), thereby ensuring 
that the treatments are in general either recommended 
or inappropriate in the patients included in the indicator. 
Furthermore, a recent review showed that unjustified 
Figure 3 Prescribing quality across different outpatient clinics. Clinics A and B: university nephrology outpatient clinics; 
clinic C: non-university nephrology outpatient clinic. Ind 1: patients with hypertension prescribed antihypertensives; ind 2: 
patients with albuminuria prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors; ind 4: patients on multiple 
antihypertensives prescribed a combination of RAAS inhibitors and diuretics; ind 6: patients aged 50–65 years prescribed 
statins; ind 7: patients with high phosphate levels prescribed phosphate binders; ind 10: patients prescribed dual RAAS 
blockade; ind 11: patients with high calcium levels prescribed active vitamin D; ind 12: patients with normal haemoglobin levels 
prescribed erythropoietin-stimulating agents; ind 13: patients with an estimated glomerular filtration rate (eGFR) lower than 
30 mL/min/1.73 m2 prescribed high-dose non-steroidal anti-inflammatory drugs (NSAIDs); ind 14: patients with diabetes and 
an eGFR lower than 30 mL/min/1.73 m2 prescribed metformin; ind 15: patients with an eGFR lower than 50 mL/min/1.73 m2 
prescribed high-dose digoxin; ind 16: patients prescribed a combination of NSAIDs, RAAS inhibitors and diuretics. 95% CIs 
were calculated based on included number of patients in the denominator of each indicator. *Significant difference between two 
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case-mix corrections can mask actual differences in 
quality of care.13 Therefore, no case-mix adjustment was 
made when applying the PQIs.
This study assessed the prescribing quality in a cross-sec-
tional manner, since the PQIs were defined as cross-sec-
tional measures. This may lead to including patients who 
reached abnormal risk factor levels for the first time. In 
some cases, the healthcare provider may decide to post-
pone the start of treatment until a next measurement 
to make sure that the abnormal risk factor level persists. 
This also holds for discontinuation of active vitamin D in 
patients with elevated calcium levels and ESA in patients 
with normal haemoglobin levels. Furthermore, it is 
possible that the laboratory results became available after 
the visit. Therefore, the healthcare provider may not have 
been aware at the time of the visit that they should start 
or discontinue medication. In the diabetes field, it has 
been proposed that indicators using multiple time points 
may give a more accurate assessment of the prescribing 
quality.14 15 Such indicators assess whether the healthcare 
providers start or intensify treatment when patients do 
not return to normal risk factor levels.
Differences between clinics may in part be due to differ-
ences in the underlying patient population such as age 
and comorbidity. All PQIs focusing on recommended 
treatment with antihypertensives, RAAS inhibitors, statins 
and phosphate binders, however, have an age limit which 
excludes the older, more frail patients. Diabetes prev-
alence was higher in clinic A, which may have affected 
prescribing. Other studies indicate that CKD patients 
with diabetes receive better quality of care in general,16 
and have higher prescription rates of RAAS inhibitors 
and statins.3 There were also differences in data collec-
tion methods between the clinics. Although we were 
able to extract and combine the data in order to make 
comparisons possible, there were some differences in 
availability of measurement values. Furthermore, data 
from the blood pressure and laboratory measurements 
were sometimes missing (table 2), with the highest rate 
of missingness for clinic B (online supplementary table 
2). This could have influenced the outcome of the PQIs, 
since patients with unknown values were not included in 
the PQIs. We can only speculate why these values were 
missing, and how this may have influenced the assess-
ments. It could be that the blood pressure and laboratory 
measurements were not performed, not recorded or lost 
during data extraction. Our aim was not to explain differ-
ences in prescribing. To understand the causes under-
lying prescribing variation, future studies should look 
at the influence of patient, prescriber and organisation 
characteristics.
In conclusion, using a novel set of PQIs assessing 
prescribing quality with patient level data we successfully 
identified several areas for potential improvement. This 
included potential underprescribing of RAAS inhibi-
tors and statins and potential overprescribing of active 
vitamin D in secondary care patients with CKD stages 
3–5. This information can support clinicians to identify 
the patients that are truly in need of improved treatment. 
We observed differences in prescribing quality between 
the CKD stages and between the outpatient clinics. We 
conclude that monitoring of the prescribing quality with 
PQIs in secondary care and stratification on CKD stage 
can be used to identify priority areas for quality improve-
ment initiatives.
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